PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
27649046-0	2017	MnTBAP Inhibits Bleomycin-Induced Pulmonary Fibrosis by Regulating VEGF and Wnt Signaling.	Bleomycin	16-25	vascular endothelial growth factor A	Homo sapiens	67-71	
33787325-10	2021	Moreover, bleomycin was found to activate VEGF/Src signaling which increased PMCs permeability.	Bleomycin	10-19	vascular endothelial growth factor A	Homo sapiens	42-46	
33787325-11	2021	In vivo, inhibition of VEGF/Src signaling prevented bleomycin-induced sub-pleural pulmonary fibrosis.	Bleomycin	52-61	vascular endothelial growth factor A	Homo sapiens	23-27	
27649046-6	2017	Overall, the data show that the superoxide scavenger MnTBAP attenuates bleomycin-induced pulmonary fibrosis by targeting VEGF and Wnt signaling pathways.	Bleomycin	71-80	vascular endothelial growth factor A	Homo sapiens	121-125	
26425798-0	2016	A proteomics approach to identifying key protein targets involved in VEGF inhibitor mediated attenuation of bleomycin-induced pulmonary fibrosis.	Bleomycin	108-117	vascular endothelial growth factor A	Homo sapiens	69-73	
26425798-6	2016	Mechanistic/mammalian target of rapamycin (mTOR) and extracellular signal-regulated kinase (ERK) were identified to be key mediators of pro- and antifibrotic response, where bleomycin (BLM) treatment resulted in increased expression and VEGF inhibitor treatment attenuated expression of mTOR and ERK.	Bleomycin	174-183	vascular endothelial growth factor A	Homo sapiens	237-241	
25919965-0	2015	Nitric oxide mediates bleomycin-induced angiogenesis and pulmonary fibrosis via regulation of VEGF.	Bleomycin	22-31	vascular endothelial growth factor A	Homo sapiens	94-98	
25919965-3	2015	We demonstrate that bleomycin treatment induces angiogenesis, and inhibition of the central angiogenic mediator VEGF using anti-VEGF antibody CBO-P11 significantly attenuates bleomycin-induced pulmonary fibrosis in vivo.	Bleomycin	175-184	vascular endothelial growth factor A	Homo sapiens	112-116	
25919965-3	2015	We demonstrate that bleomycin treatment induces angiogenesis, and inhibition of the central angiogenic mediator VEGF using anti-VEGF antibody CBO-P11 significantly attenuates bleomycin-induced pulmonary fibrosis in vivo.	Bleomycin	175-184	vascular endothelial growth factor A	Homo sapiens	128-132	
25919965-4	2015	Bleomycin-induced nitric oxide (NO) was observed to be the key upstream regulator of VEGF via the PI3k/Akt pathway.	Bleomycin	0-9	vascular endothelial growth factor A	Homo sapiens	85-89	
25919965-5	2015	VEGF regulated other important angiogenic proteins including PAI-1 and IL-8 in response to bleomycin exposure.	Bleomycin	91-100	vascular endothelial growth factor A	Homo sapiens	0-4	
25919965-6	2015	Inhibition of NO and VEGF activity significantly mitigated bleomycin-induced angiogenic and fibrogenic responses.	Bleomycin	59-68	vascular endothelial growth factor A	Homo sapiens	21-25	
25919965-7	2015	NO and VEGF are key mediators of bleomycin-induced pulmonary fibrosis, and could serve as important targets against this debilitating disease.	Bleomycin	33-42	vascular endothelial growth factor A	Homo sapiens	7-11	
19520917-6	2010	Activation of PI3K/Akt by bleomycin also led to transcriptional activation and protein expression of hypoxia-inducible factor-1alpha (HIF-1alpha) and vascular endothelial growth factor, which contributed to the fibroproliferative and collagen-inducing effects of bleomycin.	Bleomycin	26-35	vascular endothelial growth factor A	Homo sapiens	150-184